{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:17:53Z","timestamp":1758273473158},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.pcad.2009.01.001","type":"journal-article","created":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T08:35:40Z","timestamp":1241426140000},"page":"487-502","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Insights From the Treating to New Targets Trial"],"prefix":"10.1016","volume":"51","author":[{"given":"David D.","family":"Waters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2009.01.001_bib1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","article-title":"Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?","volume":"93","author":"Waters","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2009.01.001_bib4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4065\/83.8.870","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease","volume":"83","author":"Shepherd","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pcad.2009.01.001_bib7","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2009.01.001_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1751-7176.2008.07851.x","article-title":"The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study","volume":"10","author":"Kostis","year":"2008","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.pcad.2009.01.001_bib9","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2007.12.054","article-title":"Intensive lipid-lowering with atorvastatin for secondary prevention in patients with coronary artery bypass surgery","volume":"51","author":"Shah","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.amjcard.2008.07.023","volume":"102","author":"Johnson","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-147-1-200707030-00002","article-title":"Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease","volume":"147","author":"Wenger","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/hrt.2007.122325","article-title":"Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study","volume":"94","author":"Wenger","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2009.01.001_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","article-title":"Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)","volume":"100","author":"LaRosa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib15","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib16","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2006.07.041","article-title":"Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study","volume":"48","author":"Waters","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCULATIONAHA.106.625574","article-title":"Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study","volume":"115","author":"Khush","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib18","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ahj.2008.05.032","article-title":"Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial","volume":"156","author":"Mark","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2009.01.001_bib19","article-title":"Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study","author":"Taylor","year":"2008","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.pcad.2009.01.001_bib20","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1161\/CIRCULATIONAHA.105.583815","article-title":"South Asians and cardiovascular risk. What clinicians should know","volume":"113","author":"Gupta","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2009.01.001_bib22","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the Cholesterol and Recurrent Events (CARE) trial","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib23","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial","volume":"26","author":"Keech","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2009.01.001_bib24","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib29","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome. An American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1161\/01.CIR.0000140677.20606.0E","article-title":"Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults","volume":"110","author":"Malik","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib31","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCULATIONAHA.104.516948","article-title":"Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn study","volume":"112","author":"Dekker","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib32","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for the development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib34","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1681\/ASN.2005070779","article-title":"Effect of pravastatin in people with diabetes and chronic kidney disease","volume":"16","author":"Tonelli","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2009.01.001_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib36","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib37","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","article-title":"Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease","volume":"14","author":"Tonelli","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2009.01.001_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.104.517565","article-title":"Effect of pravastatin on rate of kidney function loss in patients with or at risk for coronary disease","volume":"112","author":"Tonelli","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study","volume":"57","author":"Athyros","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.pcad.2009.01.001_bib40","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.amjcard.2005.12.052","article-title":"Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate","volume":"97","author":"Vidt","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib41","doi-asserted-by":"crossref","first-page":"F53","DOI":"10.1152\/ajprenal.00041.2008","article-title":"Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability","volume":"295","author":"Zhou","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib42","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib43","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0735-1097(00)00973-6","article-title":"Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (post-CABG) trial. Post-CABG Trial investigators","volume":"36","author":"Domanski","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/01.CIR.102.2.157","article-title":"Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators","volume":"102","author":"Knatterud","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib46","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib48","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low-density lipoprotein with intensive statin therapy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib49","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/CIRCULATIONAHA.107.694117","article-title":"Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival","volume":"116","author":"Leeper","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib50","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2009.01.001_bib51","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(05)67702-1","article-title":"Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study)","volume":"366","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","article-title":"Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial","volume":"320","author":"Iso","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"A placebo-controlled trial of high-dose atorvastatin in patients with recent stroke or transient ischemic attack","volume":"355","author":"Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study Steering Committee","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib54","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1212\/01.wnl.0000296277.63350.77","article-title":"Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study","volume":"70","author":"Goldstein","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.pcad.2009.01.001_bib55","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.cardfail.2006.05.003","article-title":"Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials","volume":"12","author":"Khush","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2009.01.001_bib56","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.0000084539.58092.DE","article-title":"Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy","volume":"108","author":"Node","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2009.01.001_bib57","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacc.2005.06.088","article-title":"Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure","volume":"47","author":"Sola","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","article-title":"The effect of simvastatin on the incidence of heart failure in patients with coronary heart disease","volume":"3","author":"Kjekshus","year":"1997","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2009.01.001_bib59","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial","volume":"129","author":"Lewis","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib60","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2009.01.001_bib61","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib62","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial","volume":"372","author":"GISSI-HF Investigators","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2009.01.001_bib63","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2009.01.001_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062009000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062009000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T20:25:49Z","timestamp":1558297549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062009000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0033062009000024"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2009.01.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}